Middle East & Africa Hypertrophic and Keloid Scar Treatment Market Growth Drivers by 2027

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Scar Type (Hypertrophic and Keloid), Product Type (Laser Products, Topical Products, Injectables, Other Products), and End User (Hospitals, Clinics, and Homecare)

Historic Data: 2018-2019 | Base Year: 2020 | Forecast Period: 2021-2027
  • Status : Published
  • Report Code : TIPRE00025198
  • Category : Life Sciences
  • No. of Pages : 90
  • Available Report Formats : pdf-format excel-format
  • Last update date : October 19, 2021
Middle East & Africa Hypertrophic and Keloid Scar Treatment Market Growth Drivers by 2027
Report Date: October 19, 2021   |   Report Code: TIPRE00025198 Email: sales@theinsightpartners.com

2020 Market Size

US$ 148.07 Mn

Base year value

2027 Forecast

US$ 280.23 Mn

Projected by 2027

CAGR 2021-2027

9.5 %

Growth rate

Addressable Market

US$ 1,514.79 Mn

(2021-2027)

The hypertrophic and keloid scar treatment market in Middle East & Africa is expected to grow from US$ 148.07 million in 2020 to US$ 280.23 million by 2027; it is estimated to grow at a CAGR of 9.5% from 2020 to 2027.



UAE, Saudi Arabia, and South Africa are major economies in Middle East & Africa. Benefits of laser treatment is the major factor driving the growth of the Middle East & Africa hypertrophic and keloid scar treatment market. Technological advancements have led to the successful use of laser especially 585 nm PDL, Q-switched 532 nm frequency-doubled Nd: YAG, and CO2 lasers, among other types—for treating hypertrophic and keloid scars. The laser treatment helps prevent scar formation after surgery; it reduces pain and itching and allows movement that is otherwise limited by the scar. The treatment is widely employed to treat hypertrophic and keloid scars caused by burns. According to the “Laser Management of Hypertrophic Burn Scars: a Comprehensive Review,” published in January 2020, burn-related injury follows more than 70% of hypertrophic scars. Similarly, according to the World Health Organization (WHO), burn is the major public health problem. Every year, ~265,000 deaths are registered due to scalds, electrical burns, and other burn forms. Moreover, 90% of the burn incidences are reported in low- and middle-income countries. As excessive collagen deposition leads to the generation of hypertrophic scars that lead to raised scars, laser treatment proves to be effective against them. Moreover, due to being a minimally invasive method, it ensures reduced scar thickness, pain, and postoperative recovery period. It also helps prevent the need for surgical excision and improves skin pigmentation, pliability, height, pruritus, texture, and heat sensitivity, among other skin conditions of the affected areas. Moreover, this treatment procedure proves to be cost-effective, especially for those opting for medical tourism. Owing to such advantages, there is high demand for the laser treatment curing hypertrophic and keloid scars, which is further anticipated to drive the market in Middle East & Africa.

Africa has reported 2,867,078 cases as of early January 2021. The number of COVID-19 cases has been increasing in South Africa (1,113,349), Iran (1,249,507), and Turkey (2,255,607). Economic uncertainties and ongoing conflicts are worsening the situation in the region. For instance, countries such as Syria, Libya, and Yemen are experiencing violent conflict and cannot complete any public health measures. Iran was in a deep economic collapse due to the US sanctions. Till October 2020, there was a higher incidence of COVID-19 in Egypt and the Republic of South Africa than in the general picture in Africa. However, the level is low as compared to the US, the UK, and Italy. The Middle East countries have registered a growth in the number of COVID-19 cases in the last few days, with the UAE registering 106,229 cases, Saudi Arabia reporting 339,267, and South Africa indicating 692,471 confirmed cases. However, the hypertrophic and keloid scar treatment market in this pandemic is declining due to the reduced demand for dermatology treatments. The countries are mainly focused on treating COVID-19 patients, and hence, the appointments for the hypertrophic and keloid scar treatment are postponed.

24875-img1
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
 

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market Segmentation

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market – By Scar Type

  • Hypertrophic
  • Keloid

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market – By Product Type

  • Injectables
  • Topical
    • Gels
    • Silicone Sheets
    • Creams
    • Other
  • Laser
    • CO2
    • Pulse-Dyed
    • Other
  • Other

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market – By End User

  • Hospitals
  • Clinics
  • Homecare

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market, by Country

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Middle East & Africa Hypertrophic and Keloid Scar Treatment Market-Companies Mentioned

  • Alliance Pharma PLC
  • HRA Pharma
  • Mölnlycke Health Care AB.
  • Newmedical Technology Inc.
  • Perrigo Company plc
  • Smith & Nephew
  • Sonoma Pharmaceuticals, Inc
  • Suneva Medical

Middle East & Africa Hypertrophic and Keloid Scar Treatment Report Scope

Report Attribute Details
Market size in 2020 US$ 148.07 Million
Market Size by 2027 US$ 280.23 Million
CAGR (2020 - 2027) 9.5%
Historical Data 2018-2019
Forecast period 2021-2027
Segments Covered By Scar Type
  • Hypertrophic and Keloid
By Product Type
  • Laser Products
  • Topical Products
  • Injectables
  • Other Products
By End User
  • Hospitals
  • Clinics
  • Homecare
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Alliance Pharma PLC
  • HRA Pharma
  • M
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA